Pharmaceutical Technology on MSN

JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success

The company has made more than 50 deals for its proprietary technology as it looks forward to a potentially “transformative” ...
Monthly Prescribing Reference

Sunlenca Tablets

Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between capsid protein (p24) subunits in hexamers. Surface plasmon resonance sensorgrams ...
Morningstar

Apertura Gene Therapy Licenses Blood-Brain Barrier-Penetrant AAV Capsid to Multiple Partners Advancing Central Nervous System Treatments

Apertura has licensed its novel TfR1 capsid (TfR1 CapX) to partners targeting CNS disorders TfR1 CapX enables broad brain distribution via intravenous dosing, meeting the urgent need for a ...
Morningstar

JCR Pharmaceuticals Enhances Delivery of AAV Gene Therapy to Central Nervous System and Muscle with Novel Capsid Engineering Platform Technology

-Oral Presentation at ESGCT Highlights Potential of JCR’s Proprietary JUST-AAV Platform to Facilitate More Efficient Delivery While Reducing Liver Tropism- JCR Pharmaceuticals Co., Ltd. (TSE 4552; ...